verified SJR 0,745 · Q2 • database Scopus / SJR & Web of Science indexed

United States · Thieme Medical Publishers, I...

workspace_premium Q2 — Hematology lock Subscription

Seminars in Thrombosis and Hemostasis

Seminars in Thrombosis and Hemostasis is a journal indexed in SJR in Hematology and Cardiology and Cardiovascular Medicine with an H index of 116. It has an SJR impact factor of 0,745 and it has a best quartile of Q2. It is published in English. It has an SJR impact factor of 0,745.

ISSN: 0094-6176

Publisher: Thieme Medical Publishers, Inc.

Category: Hematology

Indexation: verifiedScopus / SJR verifiedWeb of Science

open_in_new Portal NPD menu_book Guidelines NPD

schedule CountryOfPapers database fields

SJR Impact Factor trending_up

0,745 Q2

H-index 116

Acceptance rate pie_chart

24% Selective

Source Acceptance_Rate

Time to publication hourglass_top

NPD

Field NPD

Publication cost (APC) payments

NPD Subscription

Non-OA path NPD

Metrics

Scimago and CountryOfPapers database fields

Scopus / SJR Web of Science

SJR Impact

0,745

H-index

116

Docs (year)

177

Docs 3y

333

Total refs

12099

Cites 3y

986

Citable 3y

260

Cites/Doc 2y

3.19

Ref/Doc

68.36

Immediate OA

—

Embargoed OA

NPD

Non OA / Submission

—

shield Researcher voice

Name good journals. Call out predatory ones.

Share what peer review, fees, and timelines were really like. Praise fair editors. Flag APC traps, fake metrics, or spam solicitations — with facts from your submission.

Fair & fast peer review Clear APC / no surprise fees Suspected predatory Fake impact claims

rate_review Write an honest review

Researcher reviews

sentiment_dissatisfied No reviews yet — be the first to share an honest experience.

Publication speed *

Review quality *

Edition and editorial team *

Institutional email or ORCID * * Only to validate authenticity — identity is not shown publicly.

Best articles by citations

Reduction in Thrombus Extension and Clinical End Points in Patients after Initial Treatment for Deep Vein Thrombosis with the Fixed-Dose Body Weight-Independent Low Molecular Weight Heparin Certoparin

Why Is Factor Xa Not a Better Target Than Factor IIa for Therapeutic Inhibition of Coagulation?

von Willebrand Factor Collagen-Binding (Activity) Assay in the Diagnosis of von Willebrand Disease: A 15-Year Journey

Virus Safety of Hemophilia Treatment in Germany and Austria-a Review of the Past 15 Years: A Eulogy for the 70th birthday of Professor Dr. rer. nat. Norbert Heimburger

Venous Thromboembolism in Medical Patients-The Scope of the Problem

Venous Thromboembolism and Its Treatment in High-Risk Groups

Upper Extremity Deep Venous Thrombosis

Virus Safety of Hemophilia Treatment in Germany and Austria: A Tribute to Norbert Heimburger, Ph.D.

Sixteen Years of Treatment with Pasteurized Human Clotting Factor Concentrates in Children and Adolescents: A Pharmacosurveillance Investigation Comprising 727 Patient Years

Response of von Willebrand Factor Parameters to Desmopressin in Patients with Type 1 and Type 2 Congenital von Willebrand Disease: Diagnostic and Therapeutic Implications

Replacement Therapy with Virus-Inactivated Clotting Factor Concentrates in Patients with Severe Hemophilia in Heidelberg

Regulatory Role of Cytokines in Disseminated Intravascular Coagulation

SHOW MORE ARTICLES

Status of Infection in Young Hemophilia Patients in Munster

Recombinant von Willebrand Factor: Preclinical Development

Recombinant von Willebrand Factor-Insight into Structure and Function through Infusion Studies in Animals with Severe von Willebrand Disease

Recombinant Antithrombin: Production and Role in Cardiovascular Disorder

Purity, Activity, and Virus Safety of a Pasteurized Antithrombin Concentrate

Proton Pump Inhibitors and Dabigatran Therapy: Impact on Gastric Bleeding and Dabigatran Plasma Levels

Prohemostatic Interventions in Liver Surgery

Production Processes of Licensed Recombinant Factor VIII Preparations

Production and Clinical Development of a Hansenula polymorpha-Derived PEGylated Hirudin

Production and Characterization of Saratin, an Inhibitor of von Willebrand Factor-Dependent Platelet Adhesion to Collagen

Prevention of Venous Thromboembolism: Focus on Mechanical Prophylaxis

Preface

FAQs

Seminars in Thrombosis and Hemostasis has an SJR of 0,745 (best quartile Q2) in the CountryOfPapers database.

Immediate OA APC is not available (NPD).

The acceptance rate recorded for Seminars in Thrombosis and Hemostasis is 24%.

Seminars in Thrombosis and Hemostasis

Metrics

Name good journals. Call out predatory ones.

Researcher reviews

Best articles by citations

FAQs

What is the SJR of Seminars in Thrombosis and Hemostasis?

What is the APC / publication cost?

What is the acceptance rate?